

Ribavirin Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 402661-00021
 Date of first issue: 11.12.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Ribavirin Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

117 16th Road

1685 Halfway house, Midrand, South Africa

Telephone : +27 11 655 3000

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Germ cell mutagenicity, Category 2
Reproductive toxicity, Category 1B
H341: Suspected of causing genetic defects.
H360Df: May damage the unborn child. Suspected

of damaging fertility.

Specific target organ toxicity - single ex-

posure, Category 3

H335: May cause respiratory irritation.

Specific target organ toxicity - repeated

exposure, Category 1

H372: Causes damage to organs through pro-

longed or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

 \rangle

Signal word : Danger

Hazard statements : H335 May cause respiratory irritation.



Ribavirin Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 402661-00021
 Date of first issue: 11.12.2015

H341 Suspected of causing genetic defects.

H360Df May damage the unborn child. Suspected of damaging

fertility.

H372 Causes damage to organs through prolonged or re-

peated exposure.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh

air and keep comfortable for breathing. Call a POISON

CENTER/ doctor if you feel unwell.

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Hazardous components which must be listed on the label:

Ribavirin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Ribavirin	36791-04-5	Acute Tox. 4; H302 Muta. 2; H341 Repr. 1B; H360Df STOT SE 3; H335 STOT RE 1; H372 (Blood)	>= 50 - < 70

For explanation of abbreviations see section 16.



Ribavirin Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 402661-00021
 Date of first issue: 11.12.2015

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause respiratory irritation.

Suspected of causing genetic defects.

May damage the unborn child. Suspected of damaging fertili-

ty.

Causes damage to organs through prolonged or repeated

exposure.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 402661-00021 Date of first issue: 11.12.2015

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides Metal oxides

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Surround spill with absorbents and place a damp covering

over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution.

Soak up with inert absorbent material.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.

Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and dis-



Ribavirin Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 402661-00021
 Date of first issue: 11.12.2015

posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust.
Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Already sensitised individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira-

tory irritants or sensitisers.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in

accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 402661-00021 Date of first issue: 11.12.2015

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
Ribavirin	36791-04-5	Wipe limit	400 μg/100 cm ²	Internal
		TWA	40 μg/m3 (OEB 3)	Internal
Cellulose	9004-34-6	OEL-RL	10 mg/m3	ZA OEL
	Further information: Occupational Exposure Limits - Restricted Limits For			
	Hazardous Chemical Agents			

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 402661-00021 Date of first issue: 11.12.2015

ommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : powder Colour : white

Odour : No data available Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available Partition coefficient: n- : Not applicable

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 30.09.2023 402661-00021 Date of first issue: 11.12.2015

Flammability (liquids) : No data available

Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

Components:

Ribavirin:

Acute oral toxicity : LD50 (Rat): 4.116 - 5.584 mg/kg

LD50 (Mouse): > 10.000 mg/kg

LD50 (Dog): >= 1.500 mg/kg



Ribavirin Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 402661-00021
 Date of first issue: 11.12.2015

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Rat): 1.554 - 1.758 mg/kg Application Route: Intraperitoneal

LD50 (Mouse): 1.268 mg/kg Application Route: Intraperitoneal

Skin corrosion/irritation

Not classified based on available information.

Components:

Ribavirin:

Remarks : No data available

May irritate skin.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Ribavirin:

Remarks : No data available

May irritate eyes.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Ribavirin:

Remarks : No data available

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:

Ribavirin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Rodent cell line

Result: positive



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 402661-00021 Date of first issue: 11.12.2015

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: negative

Genotoxicity in vivo : Test Type: dominant lethal test

Species: Rat Result: negative

Test Type: Mouse Lymphoma

Species: Mouse Result: positive

Test Type: Micronucleus test

Species: Mouse Result: positive

Germ cell mutagenicity- As-

sessment

Positive result(s) from in vivo mammalian somatic cell muta-

genicity tests.

Carcinogenicity

Not classified based on available information.

Components:

Ribavirin:

Species : Mouse
Application Route : Oral
Exposure time : 6 Months

LOAEL : 75 mg/kg body weight

Result : negative Target Organs : Blood, Testes

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 10 mg/kg body weight

Result : negative

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Species : Mouse
Application Route : Oral
Exposure time : 18 Months
Result : negative

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:

Ribavirin:



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 402661-00021 Date of first issue: 11.12.2015

Effects on fertility : Test Type: Fertility

Species: Rat, male

Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight

Symptoms: Reduced fertility

Result: positive

Test Type: Fertility Species: Mouse, male Application Route: Oral

Fertility: LOAEL: 35 mg/kg body weight

Symptoms: Reduced fertility

Result: positive

Test Type: Fertility Species: Rat, females Application Route: Oral

Fertility: NOAEL: 10 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Test Type: Fertility Species: Rat, male Application Route: Oral

Fertility: NOAEL: 160 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Development Species: Rat, female Application Route: Oral

Developmental Toxicity: LOAEL: <= 1 mg/kg body weight Symptoms: Reduced body weight, Reduced number of viable

fetuses, Skeletal malformations

Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Test Type: Development Species: Rabbit, female Application Route: Oral

General Toxicity Maternal: LOAEL: 1 mg/kg body weight Developmental Toxicity: LOAEL: 1 mg/kg body weight Symptoms: Reduced body weight, Skeletal malformations Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Test Type: Development Species: Hamster Application Route: Oral

Developmental Toxicity: LOAEL: 2,5 mg/kg body weight Symptoms: Skeletal and visceral variations, Total Resorptions

/ resorption rate

Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Test Type: Embryo-foetal development

Species: Rat



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 402661-00021 Date of first issue: 11.12.2015

Application Route: Oral

General Toxicity Maternal: NOAEL: 0,3 mg/kg body weight Embryo-foetal toxicity: LOAEL: 1 mg/kg body weight

Symptoms: Skeletal malformations

Result: positive

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

May cause respiratory irritation.

Components:

Ribavirin:

Assessment : May cause respiratory irritation.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Ribavirin:

Exposure routes : Ingestion Target Organs : Blood

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Exposure time

Ribavirin:

Species : Monkey LOAEL : 30 mg/kg Exposure time : 10 d

Target Organs : Blood, Gastrointestinal tract

Species : Rat
NOAEL : 7,6 mg/kg
Application Route : Inhalation
Exposure time : 90 d
Target Organs : Blood, Lungs

Species : Dog NOAEL : 5 mg/kg Application Route : Oral

Target Organs : Blood, Gastrointestinal tract

Species : Mouse NOAEL : 20 mg/kg Application Route : Oral



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 30.09.2023 402661-00021 Date of first issue: 11.12.2015

Exposure time : 18 Months

Target Organs : Blood, Cardio-vascular system

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Ribavirin:

Inhalation : Symptoms: Headache, Dizziness

Remarks: Based on Human Evidence

Skin contact : Remarks: May cause eye irritation.

Based on Human Evidence

Eye contact : Remarks: May cause eye irritation.

Based on Human Evidence

Ingestion : Symptoms: blood effects, immune system effects, anorexia,

Dizziness, insomnia, Fatigue, Headache, Itching, Rash, liver

function change, Gastrointestinal disturbance

SECTION 12: Ecological information

12.1 Toxicity

Components:

Ribavirin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 119 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 117 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 119

mg/I

Exposure time: 96 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 6,9

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 : > 1.000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

12.2 Persistence and degradability

No data available



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 30.09.2023 402661-00021 Date of first issue: 11.12.2015

12.3 Bioaccumulative potential

Components:

Ribavirin:

Partition coefficient: n-

octanol/water

log Pow: 0,971

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to

REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 30.09.2023 402661-00021 Date of first issue: 11.12.2015

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADR : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 402661-00021 Date of first issue: 11.12.2015

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H335 : May cause respiratory irritation.
H341 : Suspected of causing genetic defects.

H360Df : May damage the unborn child. Suspected of damaging fertili-

ty.

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Muta. : Germ cell mutagenicity Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure STOT SE : Specific target organ toxicity - single exposure

ZA OEL : South Africa. The Regulations for Hazardous Chemical

Agents, Occupational Exposure Limits

ZA OEL / OEL-RL : Occupational Exposure Limit Restricted limit - 8- hour expo-

sure or equivalent (12 hour shifts)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 402661-00021 Date of first issue: 11.12.2015

- United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

Muta. 2	H341	Calculation method
Repr. 1B	H360Df	Calculation method
STOT SE 3	H335	Calculation method
STOT RE 1	H372	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN